TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

BOTOX

OnabotulinumtoxinA Acetylcholine Release Inhibitors
Neurology Approved 1991-12-09

BOTOX (onabotulinumtoxinA) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for various neurological, muscular, and autonomic conditions in adult and pediatric patients. It is used to treat bladder dysfunctions, including overactive bladder and neurogenic detrusor overactivity, in patients who have had an inadequate response to or are intolerant of anticholinergic medications. The drug is also approved for the prophylaxis of chronic migraine in adults and the treatment of spasticity, cervical dystonia, blepharospasm, and strabismus. Additionally, it is indicated for the management of severe axillary hyperhidrosis that is inadequately managed by topical agents.

Source: FDA Label • AbbVie • Acetylcholine Release Inhibitor

How BOTOX Works

BOTOX blocks neuromuscular transmission by binding to acceptor sites on motor or autonomic nerve terminals and inhibiting the release of the neurotransmitter acetylcholine. This inhibition is achieved as the neurotoxin cleaves SNAP-25, a protein necessary for the successful docking and release of acetylcholine from vesicles within nerve endings. When injected into target tissues, the drug produces localized chemical denervation, resulting in a reduction of muscle activity or sweat gland production. In the bladder, the drug affects the efferent pathways of detrusor activity via this same inhibition of acetylcholine release.

Source: FDA Label
23
Indications
--
Phase 3 Trials
2
Priority Reviews
34
Years on Market

Details

Status
Prescription
First Approved
1991-12-09
Routes
SINGLE-USE
Dosage Forms
VIAL

Companies

Active Ingredient: OnabotulinumtoxinA

BOTOX Approval History

Loading approval history...

What BOTOX Treats

10 indications

BOTOX is approved for 10 conditions since its original approval in 1991. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Overactive Bladder
  • Urinary Incontinence
  • Detrusor Overactivity
  • Neurogenic Detrusor Overactivity
  • Chronic Migraine
  • Spasticity
  • Cervical Dystonia
  • Axillary Hyperhidrosis
Source: FDA Label

BOTOX Boxed Warning

DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threat...

Drugs Similar to BOTOX

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DETROL
TOLTERODINE TARTRATE
2 shared
UPJOHN
Shared indications:
Overactive BladderUrinary Incontinence
MYRBETRIQ
MIRABEGRON
2 shared
APGDI
Shared indications:
Overactive BladderNeurogenic Detrusor Overactivity
TOVIAZ
FESOTERODINE FUMARATE
2 shared
Pfizer
Shared indications:
Overactive BladderNeurogenic Detrusor Overactivity
Xeomin
incobotulinumtoxinA
2 shared
MERZ PHARMS
Shared indications:
Cervical DystoniaBlepharospasm
BACLOFEN
BACLOFEN
1 shared
LANNETT CO INC
Shared indications:
Spasticity
DARIFENACIN
DARIFENACIN HYDROBROMIDE
1 shared
MACLEODS PHARMS LTD
Shared indications:
Overactive Bladder
DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE
1 shared
ALEMBIC
Shared indications:
Overactive Bladder
DAXXIFY
DAXIBOTULINUMTOXINA-LANM
1 shared
REVANCE THERAPEUTICS, INC.
Shared indications:
Cervical Dystonia
DETROL LA
TOLTERODINE TARTRATE
1 shared
UPJOHN
Shared indications:
Overactive Bladder
DIASTAT ACUDIAL
DIAZEPAM
1 shared
BAUSCH
Shared indications:
Spasticity
DIAZEPAM INTENSOL
DIAZEPAM
1 shared
Hikma
Shared indications:
Spasticity
FLEQSUVY
BACLOFEN
1 shared
AZURITY
Shared indications:
Spasticity
GABLOFEN
BACLOFEN
1 shared
PIRAMAL CRITICAL
Shared indications:
Spasticity
GEMTESA
VIBEGRON
1 shared
SUMITOMO PHARMA AM
Shared indications:
Overactive Bladder
MIRABEGRON
MIRABEGRON
1 shared
ASCENT PHARMS INC
Shared indications:
Overactive Bladder
MYOBLOC
Botulinum Toxin Type B
1 shared
ELAN PHARM
Shared indications:
Cervical Dystonia
MYRBETRIQ GRANULES
MIRABEGRON
1 shared
APGDI
Shared indications:
Overactive Bladder
ONTRALFY
TIZANIDINE HYDROCHLORIDE
1 shared
FIDELITY BIOPHARMA
Shared indications:
Spasticity
OXYTROL
OXYBUTYNIN
1 shared
AbbVie
Shared indications:
Overactive Bladder
OZOBAX DS
BACLOFEN
1 shared
METACEL PHARMS LLC
Shared indications:
Spasticity
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BOTOX FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication Treatment of neurogenic detrusor overactivity (N...

⚠️ BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptos...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.